PubRank

Campbell McInnes

Author PubWeight™ 25.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol 2010 1.66
2 Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A 2005 1.57
3 Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem 2010 1.32
4 Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 2005 1.31
5 Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009 1.14
6 Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure 2003 1.09
7 REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chembiochem 2006 1.03
8 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 2004 1.02
9 Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org Biomol Chem 2004 0.98
10 Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem Pharmacol 2009 0.98
11 Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. ChemMedChem 2009 0.97
12 Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure 2003 0.96
13 Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov 2014 0.90
14 Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly. J Med Chem 2013 0.89
15 Protein structures in virtual screening: a case study with CDK2. J Med Chem 2006 0.86
16 Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol 2010 0.86
17 Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chem Biol 2006 0.82
18 Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg Med Chem Lett 2004 0.81
19 Functional characterization and identification of mouse Rad51d splice variants. BMC Mol Biol 2009 0.80
20 Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. J Med Chem 2010 0.78
21 Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem 2014 0.78
22 Functional characterization of the RAD51D E233G genetic variant. Pharmacogenet Genomics 2009 0.77
23 Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells. ACS Chem Biol 2012 0.77
24 Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs 2006 0.77
25 Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe. Bioorg Med Chem Lett 2002 0.76
26 Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor α and β subtypes: a molecular modeling study. PLoS One 2013 0.75